Effect of Thromboprophylaxis on Clinical Outcomes After COVID-19 Hospitalization
- terminated early
- Enrollment terminated early because of a lower than anticipated event rate and declining COVID-19 hospitalizations
Authors' conclusion
The incidence of death or thromboembolism was low in this cohort of patients discharged after hospitalization with COVID-19. Because of early enrollment termination, the results were imprecise and the study was inconclusive.
Study context
- Population
- Adults hospitalized with COVID-19 for ≥48 hours and ready for discharge, without requirement for or contraindication to anticoagulation36 [3.0%] lost to follow-up
- Participants
- 1,217 adults
- Comparison
- Apixaban 2.5 mg twice daily vs placebo for 30 days after discharge
- Primary endpoint
- Composite of:
- Death
- Arterial thromboembolism
- VTE
- Follow-up
- 30 days
Methodological detailsdouble-blind, placebo-controlled, prospective, 127 US hospitals, Conducted 2021 to 2022
- Double-blind
- Placebo-controlled
- Prospective
- 127 US hospitals
- Conducted 2021 to 2022
Primary result
As reported in the abstract
Further findings
Permanent discontinuation of study drug · day 30
Safety
Major bleeding · 30 days
Clinically relevant nonmajor bleeding · 30 days
Original publication
Effect of Thromboprophylaxis on Clinical Outcomes After COVID-19 Hospitalization. Ann Intern Med. Published 21 March 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →